CD300C and Alzheimer disease: This study is the first to demonstrate the potential of CD300c, a protein involved in the regulation of monocyte differentiation, in AD treatment and that the administration of a humanized anti-CD300c antibody, CB201, improves behavior and reduces Aβ deposition in AD mice.